NASDAQ:TVTX

Travere Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TVTX

*Your capital is at risk

$42.96

-2.08 (-4.62%)

At Close: Jun 02, 2026

Travere Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -70.32. In total, the insiders bought 712.5K and sold 296.71K TVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-70.32
● Buy	712.5K shares
● Sell	296.71K shares
72% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Feb 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -70.32. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 05, 2026 Sell	Common Stock S-Sale	Baynes Roy D. Director	Director	4 500 Value: $209.9K
May 05, 2026 Buy	Stock option (right to buy) M-Exempt	Baynes Roy D. Director	Director	4 500 Value: $82.2K
May 05, 2026 Buy	Common Stock M-Exempt	Baynes Roy D. Director	Director	4 500 Value: $82.2K
May 05, 2026 Sell	Common Stock S-Sale	Cline Christopher R. Chief Financial Officer	C-Suite Officer	2 181 Value: $101.7K
May 05, 2026 Sell	Common Stock S-Sale	Inrig Jula Chief Medical Officer	Officer	2 174 Value: $101.4K
May 05, 2026 Sell	Common Stock S-Sale	Reed Elizabeth E Chief Legal Officer And GC	Officer	2 174 Value: $101.4K
May 04, 2026 Buy	Performance-based restricted stock units M-Exempt	Heerma Peter Chief Commercial Officer	Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Common Stock M-Exempt	Dube Eric M Chief Executive Officer	CEO / President	22 500 Value: $1.01M
May 04, 2026 Buy	Performance-based restricted stock units A-Award	Dube Eric M Chief Executive Officer	CEO / President	45 000 Value: $2.02M
May 04, 2026 Buy	Employee stock option (right to buy) M-Exempt	Inrig Jula Chief Medical Officer	Officer	20 000 Value: $448.0K
May 04, 2026 Buy	Performance-based restricted stock units A-Award	Inrig Jula Chief Medical Officer	Officer	8 500 Value: $381.7K
May 04, 2026 Buy	Performance-based restricted stock units M-Exempt	Inrig Jula Chief Medical Officer	Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Common Stock M-Exempt	Heerma Peter Chief Commercial Officer	Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Performance-based restricted stock units A-Award	Heerma Peter Chief Commercial Officer	Officer	8 500 Value: $381.7K
May 04, 2026 Buy	Common Stock M-Exempt	Meckler Jeffrey A Director	Director	8 000 Value: $130.6K
May 04, 2026 Sell	Common Stock S-Sale	Meckler Jeffrey A Director	Director	8 000 Value: $360.0K
May 04, 2026 Buy	Stock option (right to buy) M-Exempt	Meckler Jeffrey A Director	Director	8 000 Value: $130.6K
May 04, 2026 Buy	Common Stock M-Exempt	Rote William E. Chief Research Officer	Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Performance-based restricted stock units A-Award	Rote William E. Chief Research Officer	Officer	8 500 Value: $381.7K
May 04, 2026 Sell	Common Stock S-Sale	Inrig Jula Chief Medical Officer	Officer	20 000 Value: $900.0K
May 04, 2026 Buy	Common Stock M-Exempt	Cline Christopher R. Chief Financial Officer	C-Suite Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Performance-based restricted stock units M-Exempt	Dube Eric M Chief Executive Officer	CEO / President	22 500 Value: $1.01M
May 04, 2026 Buy	Performance-based restricted stock units M-Exempt	Cline Christopher R. Chief Financial Officer	C-Suite Officer	4 250 Value: $190.9K
May 04, 2026 Buy	Performance-based restricted stock units A-Award	Cline Christopher R. Chief Financial Officer	C-Suite Officer	8 500 Value: $381.7K
May 04, 2026 Buy	Common Stock M-Exempt	Inrig Jula Chief Medical Officer	Officer	4 250 Value: $190.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TRAVERE THERAPEUTICS, INC.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...

Read Full Profile Here